Sökning: onr:"swepub:oai:DiVA.org:oru-107868" >
Expert Opinion on D...
Expert Opinion on Dose Regimen and Therapeutic Drug Monitoring for Long-Term Use of Dalbavancin : Expert Review Panel
-
- Senneville, Eric (författare)
- Infectious Diseases department, Gustave Dron Hospital 59200 Tourcoing, University of Lille, France
-
- Cuervo, Guillermo (författare)
- Department of Infectious Diseases, Hospital Clinic of Barcelona - IDIBAPS, University of Barcelona, Barcelona, Spain
-
- Gregoire, Matthieu (författare)
- Nantes Université, CHU Nantes, Service de Pharmacologie Clinique, F-44000 Nantes, France; Nantes Université, CHU Nantes, Cibles et médicaments des infections et de l'immunité, IICiMed, UR 1155, F-44000 Nantes, France
-
visa fler...
-
- Hidalgo-Tenorio, Carmen (författare)
- Infectious Diseases Unit, Hospital Universitario Virgen de las Nieves, Granada, Spain; Instituto de Investigación Biosanitario de Granada (IBS-Granada), Granada, Spain
-
- Jehl, Francois (författare)
- Associate Professor, Laboratory of Clinical Microbiology, University Hospital of Strasbourg, France
-
- Miro, Jose M (författare)
- Department of Infectious Diseases, Hospital Clinic of Barcelona - IDIBAPS, University of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
-
- Seaton, R Andrew (författare)
- Consultant in Infectious Diseases, NHS Greater Glasgow and Clyde, United Kingdom
-
- Söderquist, Bo, 1955- (författare)
- Örebro universitet,Institutionen för medicinska vetenskaper
-
- Soriano, Alex (författare)
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; Department of Infectious Diseases, Clinic of Barcelona, University of Barcelona, Spain
-
- Thalhammer, Florian (författare)
- Department of Urology, Medical University of Vienna, Austria
-
- Pea, Federico (författare)
- Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Italy; Clinical Pharmacology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
-
visa färre...
-
(creator_code:org_t)
- Elsevier, 2023
- 2023
- Engelska.
-
Ingår i: International Journal of Antimicrobial Agents. - : Elsevier. - 0924-8579 .- 1872-7913. ; 62:5
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- BACKGROUND: Dalbavancin is a lipoglycopeptide with a long elimination half-life, currently licensed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. Dalbavancin's potential in treating off-label complex gram-positive infections is promising and real-world experience in treating such infections is growing. However, clear guidance on extended dosing regimens is lacking.OBJECTIVES: We aim to provide clear expert opinion based on recent pharmacokinetic literature and expert and real-world experience in infection areas that require >2 weeks of treatment.METHODS: A single face-to-face meeting was held in September 2022 to collate expert opinion and present safety data of dalbavancin use in these clinical indications. A survey was completed by all authors on their individual experience with dalbavancin which highlighted the heterogeneity in the regimens used. RESULTS: After review of the survey data and recent literature, we present expert panel proposals which accommodate different healthcare settings and resource availability, and centre around the length of treatment duration including up to, or exceeding, 6 weeks. To achieve adequate dalbavancin concentrations for up to 6 weeks, 3,000mg of dalbavancin should be given over 4 weeks for the agreed complex infections requiring >2 weeks treatment. Therapeutic drug monitoring (TDM) is advised for longer treatment durations and in case of renal failure. Specific dosing recommendations for other special populations require further investigation.CONCLUSIONS: These proposals based on expert opinion have been defined to encourage best practice with dalbavancin to optimise its administration beyond the current approved licenced dose across different healthcare settings.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)
Nyckelord
- Antibacterial
- Dalbavancin
- Guidance
- Infection
- Therapeutic Drug Monitoring
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Senneville, Eric
-
Cuervo, Guillerm ...
-
Gregoire, Matthi ...
-
Hidalgo-Tenorio, ...
-
Jehl, Francois
-
Miro, Jose M
-
visa fler...
-
Seaton, R Andrew
-
Söderquist, Bo, ...
-
Soriano, Alex
-
Thalhammer, Flor ...
-
Pea, Federico
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Medicinska och f ...
-
och Farmakologi och ...
- Artiklar i publikationen
-
International Jo ...
- Av lärosätet
-
Örebro universitet